Live Breaking News & Updates on Erdafitinib Balversa

Stay updated with breaking news from Erdafitinib balversa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial. ....

United States , France General , New Haven , Danielp Petrylak , Erdafitinib Balversa , Mamtanir Biomarker , Yohann Loriot , Early Trials Department At Gustave Roussy Institute , Cancer Signaling Networks At Yale Center , University Paris , Therapeutic Innovation , Early Trials Department , Gustave Roussy Institute , University Paris Saclay , Cancer Signaling Networks , Yale Cancer Center , Urothelial Cancer , Fgfr Altered Urothelial Cancer , Author Trial , Asco Annual Meeting , University Paris Saclay ,

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space. ....

Urothelial Carcinomas , Later Line Therapies , Metastatic Urothelial Carcinoma , Bladder Cancer , Urothelial Cancer , Urothelial Carcinoma , Later Line Therapy , Later Line Treatment , Enfortumab Vedotin , Ev 301 , Ev 201 , Sacituzumab Govitecan , Trophyu 01 , Novel Therapy ,

Dr Park on Navigating of Later-line Treatment Options in Metastatic Urothelial Carcinoma

Chandler Park, MD, MSc, FACP, discusses the navigation and selection of later-line treatments for patients with metastatic urothelial carcinoma.

....

United States , Chandler Park , Norton Cancer Institute , Genitourinary Clinical Trials , Metastatic Urothelial Cancer , Bladder Cancer , Enfortumab Vedotin , Sacituzumab Govitecan ,

Dr Daneshmand on the Investigation of Erdafitinib in NMIBC With FGFR2/3 Alterations

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations. ....

Siamak Daneshmand , University Of Southern California , Clinical Research , Clinical Scholar , Urologic Oncology , Southern California , Cancers Symposium , Non Muscle Invasive Bladder Cancer , Genitourinary Cancers , Urothelial Cancer , Onclive Tv ,

Mutation-targeted Bladder Cancer Drug Found Under-used

Bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial.
....

Bladder Cancer , Under Used , Clinical Trial , Urothelial Carcinomas ,